https://doi.org/10.1007/s10549-022-06770-6
X
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
14
Papers
65
Citations
5
h-index
1
i10-index
Xiaofeng Lan is an academic researcher from Chinese Academy of Medical Sciences & Peking Union Medical College. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology & Advanced Breast Cancer Therapies. The author has an h-index of 5, co-authored 12 publications.
Papers by this author
worksPyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial
2022 · Breast Cancer Research and Treatment · 24 citations
Combination of Palbociclib and Endocrine Therapy in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With or Without Brain Metastases
2024 · Technology in Cancer Research & Treatment · 7 citations
https://doi.org/10.1177/15330338231206986
The efficiency and safety of low‐dose apatinib combined with oral vinorelbine in pretreated <scp>HER2</scp>‐negative metastatic breast cancer
2024 · Cancer Medicine · 3 citations
https://doi.org/10.1002/cam4.7181
Apatinib and trastuzumab-based chemotherapy for heavily treated primary trastuzumab-resistant metastatic breast cancer
2024 · Journal of Cancer Research and Therapeutics · 2 citations
https://doi.org/10.4103/jcrt.jcrt_979_24
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat